Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

Objective:To evaluate the 24-month metabolic and morphological benefits obtained from replacing the protease inhibitor (PI) in a regimen with nevirapine, efavirenz or abacavir. Design and methods:NEFA was a randomized study designed to compare the efficacy of nevirapine, efavirenz or abacavir as substitutes for PI. A subset of 90 patients [abacavir (n = 29), efavirenz (n = 32), nevirapine (n = 29)] formed the metabolic study. Fasting total cholesterol (TC), high density lipoprotein cholesterol (HDL-c) and triglycerides levels were determined. Glucose homeostasis parameters were also collected. Lipodystrophy was evaluated by clinical examination and morphological measurements. Results:Treatment simplification led to overall lipid profile improvements. At 24 months, the two non-nucleoside reverse transcriptase inhibitors produced similar lipid benefits: HDL-c levels increased [efavirenz, 15% (P = 0.001); nevirapine, 21% (P < 0.001)] and TC to HDL-c ratios decreased [efavirenz, 14% (P < 0.001); nevirapine, 19% (P < 0.01)], an effect not observed in the abacavir arm. Non-HDL-c levels decreased by 10% in both the abacavir (P = 0.001) and efavirenz (P < 0.05) arms. Significant decreases in the levels of triglycerides occurred for the first year in all treatments; however, at 24 months most of the initial loss had been regained. Patients with baseline moderate or severe lipodystrophy obtained less-pronounced lipid benefits. Several insulin resistance markers showed a trend towards improvement. Conversely, no improvements in morphological abnormalities were observed. Conclusions:Replacing PI with efavirenz, nevirapine or abacavir improved the lipid profile, with more marked results in non-lipodystrophic patients. In contrast, this strategy does not seem to be effective for reversing body fat abnormalities.

[1]  G. Behrens.  Cardiovascular risk and body-fat abnormalities in HIV-infected adults. , 2005, The New England journal of medicine.

[2]  C. Gutiérrez,et al.  Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. , 2004, Obesity research.

[3]  D. Cooper,et al.  Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study , 2004, AIDS.

[4]  D. Podzamczer,et al.  Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. , 2003, The New England journal of medicine.

[5]  M. Law,et al.  An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. , 2003, Journal of acquired immune deficiency syndromes.

[6]  M. Gelato.  Insulin and carbohydrate dysregulation. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  E. Rosenberg,et al.  Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. , 2003, The Journal of clinical endocrinology and metabolism.

[8]  M. Johnson,et al.  Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After Switching from HAART to Trizivir™ Versus Continued HAART: The Trizal Study , 2003, HIV clinical trials.

[9]  C. Mantzoros,et al.  Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. , 2003, The Journal of clinical endocrinology and metabolism.

[10]  W. Powderly,et al.  Switching effective antiretroviral therapy: a review. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A. Garg,et al.  Lipodystrophy in Human Immunodeficiency Virus-Infected Patients , 2002 .

[12]  J. Gallant,et al.  Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use. , 2002, AIDS reviews.

[13]  J. Ribalta,et al.  Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine , 2002, AIDS.

[14]  S. Haffner,et al.  Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. , 2002, Diabetes care.

[15]  R. Blumenthal,et al.  The Significance of Measuring Non-HDL-Cholesterol , 2002 .

[16]  J. Ragnaud,et al.  Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  H. Günthard,et al.  A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. , 2002, The Journal of infectious diseases.

[18]  B. Gazzard,et al.  Changes in metabolic parameters and body shape after replacement of protease inhibitor With efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort. , 2001, Journal of acquired immune deficiency syndromes.

[19]  F. Goebel,et al.  Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. , 2001, European journal of medical research.

[20]  S. Mallal,et al.  HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study , 2001, AIDS.

[21]  B. Gazzard,et al.  Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA , 2001, AIDS.

[22]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[23]  P. Braun,et al.  Switch to Efavirenz in a Protease Inhibitor-Containing Regimen , 2001, HIV clinical trials.

[24]  Ignacio Conget,et al.  Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study , 2001, The Lancet.

[25]  R. Steigbigel,et al.  Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV Lipodystrophy , 2000, Journal of acquired immune deficiency syndromes.

[26]  J. Mallolas,et al.  Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[28]  D. Moller.  Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes , 2000, Trends in Endocrinology & Metabolism.

[29]  C. Moore,et al.  Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection , 2000, AIDS.

[30]  O. Rouvière,et al.  A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. , 1999, AIDS.

[31]  J. Gatell,et al.  Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. , 1999, AIDS.

[32]  B. Golomb,et al.  Epidemiologic aspects of lipid abnormalities. , 1998, The American journal of medicine.

[33]  M. Laakso.  Insulin resistance and coronary heart disease , 1996, Current opinion in lipidology.

[34]  Bruce Kinosian,et al.  Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios , 1994, Annals of Internal Medicine.

[35]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[36]  M. Dubé,et al.  Lipid abnormalities. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  P. Havel.  Section IV: Lipid Modulators of Islet Function Update on Adipocyte Hormones Regulation of Energy Balance and Carbohydrate/Lipid Metabolism , 2003 .

[38]  R. Blumenthal,et al.  Perspectives: The significance of measuring non-HDL-cholesterol. , 2002, Preventive cardiology.

[39]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[40]  Lipodystrophy syndrome in patients with HIV infection , 1999 .

[41]  J. Yudkin.  Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. , 1996, Annals of medicine.

[42]  T. Lohman,et al.  Anthropometric Standardization Reference Manual , 1988 .

[43]  D. Cooper,et al.  FAST TRACK: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2022 .